Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: SNDX

Syndax Pharmaceuticals, Inc.

Healthcare | Biotechnology

No licensed closing price on file for SNDX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-2.51

Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-21 11:11 UTC.

What Syndax Pharmaceuticals, Inc. does

Stemline Therapeutics is a commercial-stage biopharmaceutical company developing cancer therapies. The company has two FDA-approved medicines: Revuforj (revumenib), a menin inhibitor approved for relapsed or refractory acute leukemia with KMT2A translocation and for relapsed or refractory AML with NPM1 mutation, and Niktimvo (axatilimab-csfr), a CSF-1R blocking antibody approved for chronic graft-versus-host disease after failure of prior therapies.

Summarized from Syndax Pharmaceuticals, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-2.51
Debt/equity22.78

Revenue, margins & earnings

FY2021 Net income: $25MFY2021 Operating costs: $113M$140MFY2021FY2024: net loss $319M on revenue $24M$24MFY2024FY2025: net loss $285M on revenue $172M$172MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity
Source: SEC EDGAR · Filed 2026-07-09
Most recent filed transactions — July 2026:
  • 2026-07-09Chief Executive OfficerOption exercise32,375$206.6K
  • 2026-07-09Chief Executive OfficerSale-32,375$784.8K
  • 2026-07-09Chief Executive OfficerStock Option (Right to buy)Option exercise32,375—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Syndax Pharmaceuticals, Inc. do?

Stemline Therapeutics is a commercial-stage biopharmaceutical company developing cancer therapies.

When did SNDX last file with the SEC?

Syndax Pharmaceuticals, Inc.'s most recent SEC filing on record is a SCHEDULE 13G filed 2026-08-07. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 11:11 UTC. This page is also available as JSON at /api/data?ticker=SNDX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for SNDX and 5,000+ tickers.

Create a free account — keep SNDX
For your agent
GET /api/data?ticker=SNDX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt